Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males

Overview

Eight weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, glucose, insulin, blood lipids, and self-report measures) in young (18-25 years) overweight or obese males compared to placebo (cellulose starch). If the hypothesis is supported, alpha lipoic acid ingestion could be beneficial in reducing disease risk and enhancing metabolic dysfunction in ethnic individuals. Therefore, the purpose is to establish the impact alpha lipoic acid has on the modifiable markers associated with metabolic perturbations consistent with metabolic syndrome in males.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2016

Detailed Description

Young adults exhibit an increasing prevalence of obesity, pre-diabetes, and metabolic syndrome that contribute to increased risk of type II diabetes and cardiovascular heart disease later in life. Twenty five percent of American adults have been diagnosed with metabolic syndrome, whereas the prevalence increases to 30 % in Mexican American adults between 30-70 years old. The risk in this population may be higher based on ethnicity and the rising obesity rates in young adults and children, although the definition of metabolic syndrome in younger age has yet to be established. Factors causing metabolic syndrome are complex but include a physically inactive lifestyle, an unhealthy diet made up of saturated fat and processed foods, and inherited influences. Therefore identifying the need to intervene early with a dietary intervention in order to combat the risk for future disease is vital. It is hypothesized that 8 weeks supplementation of alpha lipoic acid (known superantioxidant already produced by the body) will significantly improve metabolic syndrome markers (e.g., excess body weight, blood pressure, glucose, insulin, blood lipids, and self-report measures) in young (18-25 years) overweight or obese males compared to placebo (cellulose starch). If the hypothesis is supported, alpha lipoic acid ingestion could be beneficial in reducing disease risk and enhancing metabolic dysfunction in young individuals. Therefore, the purpose is to establish the impact alpha lipoic acid has on the modifiable markers associated with metabolic perturbations consistent with metabolic syndrome in males.

Interventions

  • Dietary Supplement: Alpha Lipoic Acid Supplement
    • Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
  • Dietary Supplement: Placebo
    • Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.

Arms, Groups and Cohorts

  • Experimental: GNC Alpha Lipoic Acid Supplement
    • 600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
  • Placebo Comparator: Cellulose Fiber Placebo
    • 600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Effects on whole blood fasting glucose
    • Time Frame: 8 weeks
    • Measured by single drop cuvette of whole blood using Hemocue Glucose 201
  • Effects on fasting plasma inflammatory biomarkers
    • Time Frame: 8 weeks
    • Measured by ELISA kit
  • Effects on body composition (body fat, muscle mass, body weight)
    • Time Frame: 8 weeks
    • Measured by bioelectrical impedance using a Tanita floor scale

Secondary Measures

  • Effects on oxygen consumption and carbon dioxide production at rest
    • Time Frame: 8 weeks
    • Measured by True One Metabolic Cart by Parvomedics via hood
  • Effects on oxygen consumption and carbon dioxide production during exercise
    • Time Frame: 8 weeks
    • Measured by True One Metabolic Cart by Parvomedics via facemask

Participating in This Clinical Trial

Inclusion Criteria

  • Overweight or obese (body mass index 25 – 35 kg/m2) – Males (18-35 years) – Able to ingest supplement or placebo Exclusion Criteria:

  • Female (due to menstrual cycle fluctuations) – Unable to read English at the time of consent – Have a body mass index under 25 kg/m2 or over 35 kg/m2 – Diabetes – Impaired glucose tolerance (fasting plasma glucose levels >110 mg/dL – Hypertension (SBP>130mmHg or DBP>90mmHg) – Cardiovascular problems or disease – Psychiatric problems – History of alcohol abuse (intake of >500 g/wk in the last year) – Current or recent (in the past 3 years) smoking – Certain medication or dietary supplement use (medications or dietary supplements known to cause weight loss/gain or metabolic improvements/dysfunction. Paxil or (paroxetine), Prozac (fluoxetine), Remeron (mirtazapine), Zyprexa (olanzapine), Deltasone (prednisone), Thorazine (chlorpromazine), Elavil, Endep, Vanatrip (amitriptyline), Depakote (valproic acid), Allegra (fexofenadine and pseudoephedrine), Diabinese or Insulase – Symptoms of chronic or current infection – A chronic inflammatory condition – Any thyroid condition, and/or liver disease or malignancy

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of La Verne
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Sarah L. Dunn, Associate Professor of Kinesiology – University of La Verne
  • Overall Official(s)
    • Sarah L Dunn, Ph.D., Principal Investigator, University of La Verne Assistant Professor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.